Valued at USD 2.60 billion in 2024, the myasthenia gravis disease market is projected to reach USD 2.83 billion in 2025 and USD 6.19 billion by 2034, growing at a CAGR of 9.1% during the forecast period 2025–2034. Growth is driven by the increasing global prevalence of myasthenia gravis, advancements in diagnostic techniques, and the development of innovative therapies. Key players include Alexion Pharmaceuticals (AstraZeneca), Mitsubishi Tanabe Pharma, Bristol Myers Squibb, Grifols, Baxter International, CSL Behring, UCB, Prothena Biosciences, Argenx, Sanofi, Amgen, AbbVie, Pfizer, Roche, and Novartis.

Market Overview

Myasthenia gravis is a rare, chronic autoimmune disorder that causes weakness in the skeletal muscles, affecting voluntary movements. The market encompasses treatments and therapies aimed at managing symptoms and disease progression. Growing awareness, the expansion of clinical trials, and improved healthcare infrastructure in emerging markets are also contributing to market growth.

Cholinesterase Inhibitors Hold the Largest Treatment Share

Among treatment types in the myasthenia gravis disease market, cholinesterase inhibitors such as pyridostigmine hold the largest share. They are first-line treatments for the majority of patients because they improve neuromuscular transmission by inhibiting the breakdown of acetylcholine. Long-standing use and the ability to alleviate symptoms, especially in mild to moderate cases, have made cholinesterase inhibitors a staple of management and sustain steady demand across global markets.

The report segments the market by treatment type into thymectomy, cholinesterase inhibitors, and rapid immunotherapies, and by end use into hospitals and clinics.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/myasthenia-gravis-disease-market

Rapid Immunotherapies Register the Fastest Growth

Rapid immunotherapies, including IVIG and plasmapheresis, are gaining significant traction for managing acute exacerbations and severe symptoms. The segment is experiencing the fastest growth because these therapies provide rapid symptom relief for patients with refractory disease who do not respond well to other treatments. A growing number of clinical studies and the approval of newer immunosuppressive agents are driving the expansion of rapid immunotherapies.

Thymectomy Maintains a Steady Role

Thymectomy, a surgical procedure often recommended for patients with thymoma or generalized myasthenia gravis, continues to hold a crucial position but remains less widespread than pharmacological treatments. Its role in long-term disease management for certain patient subsets ensures a steady contribution to the market. Hospitals provide access to surgical interventions such as thymectomy, which reinforces their position as the largest end-use segment.

Biologic Therapies and Monoclonal Antibodies Reshape Care

A major market driver is the growing focus on biologic therapies, particularly monoclonal antibodies. Recognition of the autoimmune nature of myasthenia gravis has led to targeted treatments that modify the immune response. Approvals of eculizumab (Soliris) and ravulizumab (Ultomiris) have advanced treatment options, offering better disease control and fewer side effects than traditional therapies.

According to the National Institute of Neurological Disorders and Stroke, around 10 to 15% of patients are refractory to traditional treatments, making biologic therapies a critical option for this group. Alexion Pharmaceuticals, now part of AstraZeneca, manufactures both approved products, and competition is shifting toward monoclonal antibodies that target specific immune components to improve outcomes.

Argenx and Prothena Biosciences are developing innovative therapies that target the immune system. Larger companies such as AstraZeneca and Roche benefit from robust distribution networks and established market presence, Myasthenia Gravis Disease as while smaller biotech firms are making strides by introducing novel therapies for underserved patient groups.

Regional Outlook

North America holds the largest share, driven by advanced healthcare infrastructure, high awareness levels, and significant research and development investment, with the US leading in the adoption of biologics and immunotherapies. Europe is experiencing steady growth, although varying reimbursement policies create disparities in access to advanced treatments. Asia Pacific is witnessing the fastest growth, supported by expanding healthcare infrastructure and rising patient populations in China, India, and Japan.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market